Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsSolid TumorsProtocol groupAggressive LymphomasNeuro-OncologyTransplantationDiseaseMalignant MeningitisNHL, B-Cell Type, Diffuse Large CellNHL, B-cell type, primary Lymphoma of the central nervous system SubgroupLymphomatous MeningitisICD10C79.3C83.3MeSHCentral Nervous System NeoplasmsMeningeal CarcinomatosisSequenceFreiburg CNS-NHL StudyMARTA: RITU375/MTRX3500/CYTA2000, NHL, CNS-NHL, Ind. (PID2965) -|- MARTA - RITU375/BSLF3,2/THTP5, Cons. (PID2966)MATRIXMTRX8000/RITU375/TMZL150, CNS lymphoma, C1 (PID1859) -|- C2 (PID1860) -|- C3 (PID1861) -|- C4 (PID1864) -|- C5 (PID1865) -|- C6 (PID1866)RITU375/MTRX3500/PRCR100/VNCR2, CNS lymphoma, C1-3 (PID1896) -|- RITU375/CYTA3000, C4-6 (PID1901)RITU750/TMZL150, CNS-NHL, ind. (PID2437) -|- TMZL150, cons. (PID2438) -|- MTPR1, maint. (PID2439)ChemotherapyChemo-substanceBusulfanCarboplatinCarmustineCytarabineDexamethasoneEtoposideIfosfamideMethotrexateMethylprednisoloneProcarbazineRituximabTemozolomideThiotepaVincristineChemo-substanceBusulfanCarboplatinCarmustineCytarabineDexamethasoneEtoposideIfosfamideMethotrexateMethylprednisoloneProcarbazineRituximabTemozolomideThiotepaVincristineChemo-substanceBusulfanCarboplatinCarmustineCytarabineDexamethasoneEtoposideIfosfamideMethotrexateMethylprednisoloneProcarbazineRituximabTemozolomideThiotepaVincristineChemo-substanceBusulfanCarboplatinCarmustineCytarabineDexamethasoneEtoposideIfosfamideMethotrexateMethylprednisoloneProcarbazineRituximabTemozolomideThiotepaVincristineNo. Substances12345 RadiotherapySupportive therapySupportive substanceAciclovirAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLevetiracetamMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLevetiracetamMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLevetiracetamMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLevetiracetamMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateNo. Substances13789111213141516Protocol classificationTherapy classificationalternativecurrent standardIntensityhigh doseStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseautologous stem cell transplantationConsolidationInductionMaintenanceTherapy intentioncurativedisease controlpalliativeRisksAnemia Hb below 8g/dlCardiotoxicityDiarrheaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHepatotoxicityHyperbilirubinemiaHyperglycemiaHyperkalemiaHypokalemiaHyponatremiaIncrease AminotransferasesInfectionsLeukopeniaLymphopeniaMucositisNephrotoxicityNeuropathyNeutropeniaPneumonitisPyrexiaRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorBirnbaum TFerreri AJHouillier CIllerhaus GNayak LRubenstein JRubenstein JLSchorb EDiseaseErstdiagnose eines primären NHL des ZNS, 18-65 Jahreneudiagnostiziertes primäres ZNS-Lymphom, > 60 JahreNeudiagnostiziertes primäres ZNS-Lymphom, > 65 Jahre, ECOG 0-2Neudiagnostiziertes primäres ZNS-Lymphom, ECOG 0-2Primäres ZNS-Lymphomprimäres ZNS-Lymphom, Rezidivtherapie, Karnofsky Status größer 60%primäres ZNS-NHL, ErstdiagnoseWiederkehrendes oder refraktäres ZNS Lymphom primär oder NHL, CD20+, PS über 50Zentrales B-NHL, Erstlinie, ECOG 0-3OriginAlbert-Ludwigs University, Freiburg, Germany, Freiburger ZNS-NHL ProtokollDepartment of Neurology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, USA, North American Brain Tumor ConsortiumDivision of Hematology Oncology, University of California; Memorial Sloan-Kettering Cancer Center, New YorkHelen Diller Comprehensive Cancer Center, University of California, San Francisco, CALGB 50202 (Alliance 50202)IRCCS San Raffaele Scientific Institute, Milan, Italy, IELSG32 trialMATRix / IELSG43 StudieUniversites Paris, Paris, France, LOC network studyUniversity of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, MARTA trialProtocols in Revision 22 protocols foundMARTA - Rituximab 375 / Busulfan 3.2 / Thiotepa 5, primary central nervous system Lymphoma, consolidation therapy (PID2966 V1.0)MARTA - Rituximab 375 / Methotrexate 3500 / Cytarabine 2000, primary central nervous system Lymphoma, induction (PID2965 V1.0)MATRIX - Rituximab 375 / Carboplatin 300 / Ifosfamide 1.5 / Etoposide 100 / Dexamethasone 40, primary central nervous system Lymphoma, consolidation therapy (PID831 V2.1)MATRIX - Rituximab 375 / Methotrexate 3500 / Cytarabine 2000 / Thiotepa 30, primary central nervous system Lymphoma, induction (PID703 V2.2)Methotrexate 500/3000, Malignant Meningitis (PID1000 V1.0)Methotrexate 8000 / Rituximab 375 / Temozolomide 150, primary central nervous system Lymphoma, Cycle 1 (PID1859 V1.1)Methotrexate 8000 / Rituximab 375 / Temozolomide 150, primary central nervous system Lymphoma, Cycle 2 (PID1860 V1.3)Methotrexate 8000 / Temozolomide 150, primary central nervous system Lymphoma, Cycle 3 (PID1861 V1.3)Methotrexate 8000 / Temozolomide 150, primary central nervous system Lymphoma, cycle 4 (PID1864 V1.3)Methotrexate 8000 / Temozolomide 150, primary central nervous system Lymphoma, cycle 5 (PID1865 V1.3)Methylprednisolone 1000, primary Lymphoma of the central nervous system, maintenance (PID2439 V1.0)Rituximab 25, Malignant Meningitis (PID2571 V1.0)Rituximab 375 / Carmustine 400 / Thiotepa 5, primary central nervous system Lymphoma, conditioning, cycle 5 (PID1883 V1.0)Rituximab 375 / Cytarabine 3000 / Thiotepa 40, primary central nervous system Lymphoma, induction, cycle 3 (PID1881 V1.0)Rituximab 375 / Cytarabine 3000 / Thiotepa 40, primary central nervous system Lymphoma, induction, cycle 4 (PID1882 V1.0)Rituximab 375 / Cytarabine 3000, primary central nervous system Lymphoma, cycles 4?6 (PID1901 V1.1)Rituximab 375 / Methotrexate 3500 / Procarbazine 100 / Vincristine 2, primary central nervous system Lymphoma, cycles 1-3 (PID1896 V1.3)Rituximab 375 / Methotrexate 4000 / Ifosfamide 1.5, primary lymphoma of the central nervous system (PID3216 V1.0)Rituximab 375 / Methotrexate 8000, primary central nervous system Lymphoma, induction, cycle 1 (PID1879 V1.2)Rituximab 375 / Methotrexate 8000, primary central nervous system Lymphoma, induction, cycle 2 (PID1880 V1.2)Rituximab 750 / Temozolomide 150, primary central nervous system Lymphoma, induction therapy (PID2437 V1.0)Temozolomide 150, primary central nervous system Lymphoma, consolidation therapy (PID2438 V1.0)
